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ORIGINAL ARTICLE
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Abstract
Purpose To determine the role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomog-
raphy (CT) in children with fever of unknown origin (FUO).
Methods This retrospective single-center study included 110 children (0–18 years) with FUO who underwent FDG-PET/CT
between 2010 and 2019. The diagnostic value of FDG-PET/CT for identifying cause of fever was calculated, treatment modi-
fications after FDG-PET/CTwere assessed, and logistic regression analyses were performed to identify clinical and biochemical
factors associated with FDG-PET/CT outcome.
Results In 53 out of 110 patients (48%), FDG-PET/CT identified a (true positive) cause of fever. Endocarditis (11%), systemic
juvenile idiopathic arthritis (5%), and inflammatory bowel disorder (5%) were the most common causes of FUO. In 42 patients
(38%), no cause of fever was found on FDG-PET/CT. In 58 out of 110 patients (53%), treatment modifications were made after
FDG-PET/CT. FDG-PET/CT achieved a sensitivity of 85.5%, specificity of 79.2%, positive predictive value of 84.1%, and
negative predictive value of 80.9%. On multivariate logistic regression, C-reactive protein was positively associated with finding
a true positive focus of fever on FDG-PET/CT (OR = 1.01 (95%CI 1.00–1.02) per mg/L increase in CRP), while leukocyte count
was negatively associated with finding a true positive focus of fever (OR = 0.91 (95% CI 0.85–0.97) per 109 leukocytes/L
increase).
Conclusion FDG-PET/CT is a valuable diagnostic tool in the evaluation of children with FUO, since it may detect a true
underlying cause in almost half (48%) of all cases where none was found otherwise. It allows full-body evaluation in patients
without disease-specific symptoms on one examination. CRP and leukocyte count were significantly associated with FDG-PET/
CT results, which may contribute to a priori assessment on the outcome of FDG-PET/CT. Future research could be aimed at
evaluating more patient-specific factors to prospectively estimate the added value of FDG-PET/CT in children with FUO.
Keywords Pediatrics . Fever . Unknown . Origin . Inflammation . Infection
Introduction
Fever is defined as an elevated body temperature of 38.0–
38.3 °C or higher (1, 2). It is one of the most common symp-
toms in children presenting at the hospital. In fact, fever is the
chief complaint of children who visit the hospital in 16 to 30%
of cases (3–5). The differential diagnosis of fever is broad. The
most common cause is infection, with autoimmune disease
and malignancy as second and third causes, respectively (6,
7). In approximately 50% of infants up to 3 years old with
fever, no cause is found (8). In all children with FUO, no
definitive cause of fever is found in 10 to 20% of cases, de-
spite extensive history taking, physical examination, and lab-
oratory testing (9).
There is no widespread consensus on the definition of fever
of unknown origin (FUO), and various definitions have been
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applied throughout the years (2, 10–12). Currently, fever in
children is considered FUO after 8 or more days of febrile
illness, when a careful and thorough history taking, physical
examination, and laboratory workup failed to reveal a proba-
ble cause of the fever (7, 9, 13). If these criteria apply, but
children have fever for less than 8 days, they are sometimes
considered to have “fever without source” (FWS) (7, 9).
In the workup of febrile patients, various diagnostic tests
may be used to identify the cause of fever. These investiga-
tions often include chest radiography, abdominal ultrasonog-
raphy, laboratory tests such as C-reactive protein (CRP), leu-
kocyte count, urinalysis, and microbiologic tests. More ad-
vanced or invasive investigations may include computed to-
mography (CT), magnetic resonance imaging (MRI), immu-
nologic or organ-specific laboratory investigations, cytologic
punctures, and histologic biopsies.
In adults, 18F-fluoro-2-deoxy-D-glucose (FDG) positron
emission tomography (PET)/CT is known to be helpful for
diagnosing infectious or inflammatory foci in patients with
FUO (12, 14–20). FDG-PET/CT is already the first imaging
modality in several infectious and inflammatory diseases (21).
In children with FUO however, literature about the value of
FDG-PET/CT is scarce. In a study by Jasper et al. (22), the
results of FDG-PET/CT in 17 children with FUO were report-
ed, and in a study by Blokhuis et al. (23), 28 FDG-PET/CT
scans of children with FUO were described. Because of these
relatively low numbers of included patients, the role of FDG-
PET/CT in children with FUO remains unestablished.
Therefore, the aim of this study was to assess the value of
FDG-PET/CT in finding the cause of fever in a large group of
children with FUO and FWS.
Methods
Study design and patients
The electronic patient database of the University Medical
Center Groningen was searched for all patients aged 0 to
18 years who underwent FDG-PET/CT between 2010 and
2019. All children who underwent FDG-PET/CT for the eval-
uation of fever without a known cause were potentially eligi-
ble for inclusion. Fever was defined as a body temperature of
≥ 38.3 °C. FUOwas defined as febrile illness of multiple days,
during which careful history taking, physical examination,
and laboratory workup did not reveal a cause of fever.
Because a minimum threshold of 8 days fever is not used in
the clinic to diagnose FUO, children who had fever for mul-
tiple consecutive days, but less than 8 days, were also included
in this study.
Children who underwent FDG-PET/CT but did not have
fever, or had an already established focus of infection, inflam-
mation, or malignancy, were excluded. When children had
follow-up FDG-PET/CT scans, only the first FDG-PET/CT
scan was included.
Patient data review
The medical files of all children potentially eligible for inclu-
sion were first reviewed for the inclusion and exclusion
criteria. When children were eligible for inclusion, their med-
ical files were further reviewed. Age, gender, medical history,
duration of fever, physical examination and history taking,
laboratory values (hemoglobin, mean corpuscular volume,
thrombocyte count, hematocrit, CRP, leukocyte count and dif-
ferentiation, erythrocyte sedimentation rate), imaging results
and procedures, treatment, final diagnosis, and follow-up data
were retrieved from the medical files of all included patients.
FDG-PET/CT acquisition
All scans were performed using an integrated PET/CT system
(Biograph mCT 40 or 64 slice PET/CT, Siemens Medical
Systems, Knoxville, TN, USA) with 3 min per bed position.
Low-dose unenhanced CTwas performed for attenuation cor-
rection and anatomic mapping with 100 kV and 30 mAs.
Some patients (n = 13) underwent concomitant full-dose con-
trast-enhanced CT with a constant tube potential of 80–
120 kV and automatic adjustment of mAs in the z-direction.
Full-dose CTwould be applied when there was a suspicion of
inflammation or infection in a certain organ, and low-dose CT
would be likely not to offer a resolution high enough to accu-
rately diagnose the disease.
Patients had to fast for at least 6 hours, but some newborns
fasted for only 4 h because of risk of hypoglycemia. Patients
with a (slight) suspicion of a cardiac focus of fever also had to
adhere to a diet low in carbohydrates the day before FDG-
PET/CTwas performed. For example, this diet allowed eating
meat, fish, eggs, vegetables, and clear soup, but did not allow
potatoes, rice, bread, or milk.
After blood glucose concentrations were ensured to be be-
low 11 mmol/L, 3 MBq/kg FDG was administered intrave-
nously. PET/CT imaging was performed 60 min after FDG
administration. Data acquisition and reconstruction were in
accordance with EANM/EARL (European Association of
Nuclear Medicine/ResEARch 4 Life) guidelines (21, 24).
Some of the children had to be sedated or anesthetized when
FDG-PET/CTwas performed to prevent excessive movement
during the scan. Scans were performed from skull to mid-
thigh or to toes based on the presence or absence of complaints
in the lower extremities.
Interpretation of FDG-PET/CT results
All FDG-PET/CT scans were prospectively interpreted by nu-
clear medicine physicians as part of routine clinical care, using
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Syngo.via software (Siemens Healthineers, Erlangen,
Germany). All scans with inconclusive findings (not clear-cut
positive or negative for a cause of fever) were re-evaluated by
another nuclear medicine physician (AWJM) who was blinded
to original FDG-PET/CT interpretations, other imaging results,
clinical, laboratory, and microbiologic tests.
Diagnostic reference standard
The final diagnosis at hospital discharge was used as reference
standard for FDG-PET/CT results. This diagnosis was based
on results from all examinations performed during hospital
admission (including clinical examination, laboratory analy-
sis, microbiologic cultures, histologic biopsies, imaging re-
sults), response to treatment, and clinical or outpatient fol-
low-up. FDG-PET/CT scans that did not identify a cause of
fever were classified as true negative if patients were diag-
nosed with FUO at hospital discharge and fever had resolved
spontaneously, without a definitive cause of fever found on
any additional testing during hospital stay or during follow-up
of at least 3 months. Some children with FUO died because of
other underlying diseases. Their fever sometimes did not re-
solve, but their FDG-PET/CT scans could still be considered
true negative if their cause of death was another disease not
causing the fever. FDG-PET/CT scans were regarded as true
positive when the cause of fever found on FDG-PET/CT
corresponded with the diagnosis at hospital discharge.
Statistical analysis
Continuous variables were checked for normal distribution
using Kolmogorov-Smirnov tests. Normally distributed data
were presented as mean ± standard deviation, and non-
normally distributed data as median with interquartile range
(IQR). Sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) of FDG-PET/CT for
identifying a cause of fever in children with FUO were calcu-
lated, along with 95% confidence intervals (CIs).
Age, gender, medical history, duration of fever, laboratory
values (CRP, leukocyte count), and CT type (low-dose
unenhanced or full-dose contrast-enhanced) were analyzed
with univariate logistic regression as independent variables
and FDG-PET/CToutcome as dependent variable. The depen-
dent variable was either categorized as true positive or not true
positive (i.e., false positive, false negative, or true negative).
Corresponding odds ratios (ORs) and 95% CIs were calculat-
ed, and P < 0.05 was considered statistically significant.
Variables with P ≤ 0.10 on univariate analysis were included
in the stepwise multivariate logistic regression model. All sta-
tistical analyses were performed using IBM Statistical




338 FDG-PET/CT scans in 262 children were potentially
eligible for inclusion. After excluding follow-up FDG-
PET/CT scans and excluding patients without fever, with
a known malignancy, or any other known cause of fever
at the time FDG-PET/CT was performed, 110 FDG-PET/
CT scans in 101 patients with FUO and 9 patients with
FWS were included (Fig. 1). The 9 children with FWS
had fever for at least 5 days before FDG-PET/CT. The
FDG-PET/CT images of two interesting patients with
FUO are shown in Figs. 2 and 3. Fifty-four boys and
56 girls were included, with a median age of 9 years.
Twenty-four percent of them had no previous medical
history, 6% had received an organ or bone marrow trans-
plant, and 10% were taking immunosuppressive drugs
before FDG-PET/CT. The median duration of febrile ill-
ness before FDG-PET/CT was 25 days. Seven percent of
the patients died within 3 months after FDG-PET/CT
(Table 1). In 65% of patients, chest radiography was
performed before FDG-PET/CT. Fifty-five percent had
an abdominal ultrasound, and 11% had an abdominal
Fig. 1 After excluding follow-up FDG-PET/CT scans and excluding
patients without fever, with a known malignancy, or any other
known cause of fever at the time FDG-PET/CT was performed,
110 FDG-PET/CT scans in 101 patients with FUO and 9 patients
with FWS were included
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CT before FDG-PET/CT. In 9% of patients, no previous
diagnostic imaging was performed before FDG-PET/CT.
Imaging and additional laboratory tests performed before
FDG-PET/CT are summarized in Table 2.
Fig. 2 A 9-year-old boy was admitted to the hospital with general malaise
present for 10 days, high fever (39.5 °C), painful legs, and bloody diarrhea.
Physical examination showed increased respiratory effort, hepatomegaly,
ascites, and erythema on the hands and feet. Laboratory testing showed a
CRP of 307 mg/L, leukocyte count of 24.3 × 109/L, and erythrocyte sed-
imentation rate of 55 mm/h. MRI of the head and neck, chest radiography,
and abdominal ultrasonography did not reveal any cause of fever, and
microbiological cultures were negative for infection. As the patient did
not respond to antibiotic treatment, corticosteroid treatment was also
started. The symptoms improved, but the exact cause of the symptoms
remained unknown, and FDG-PET/CTwas performed. Coronal and sagit-
tal maximum intensity projection FDG-PET (A and B), low-dose CT (C)
and fused FDG-PET/CT (D), axial low-dose CT (E), and axial fused FDG-
PET/CT (F) showed increased FDGuptake in themajor arteries of the arms
(black arrowheads) and legs (white arrowheads), including the popliteal
artery in both knees (gray arrowheads). Based on these findings, the patient
was diagnosed with polyarteritis nodosa. As collateral findings, increased
FDG uptake in the esophagus due to irritation of a nasogastric feeding tube
(white arrow) and a small infectious process in the lower lobe of the left
lung (black arrow) were found.
Fig. 3 A 9-year-old boy presented at the hospital with anorexia, weight
loss, fatigue, and intermittent fever up to 39.5 °C. The patient had expe-
rienced these symptoms episodically over the past 18 months, but a def-
inite diagnosis had never been established. On physical examination, the
upper abdomen was tender to palpation. Laboratory examinations
showed a CRP of 49 mg/L, leukocyte count of 8.0 × 109/L, and erythro-
cyte sedimentation rate of 46 mm/h. Microbiological urine, blood, and
fecal cultures were negative. Abdominal ultrasonography and MRI
showed focal steatosis of the liver, but no possible cause of fever.
Coronal and sagittal maximum intensity projection FDG-PET (A and
B), low-dose CT (C) and fused FDG-PET/CT (D), axial low-dose CT
(E), and axial fused FDG-PET/CT (F) showed extensive FDG uptake
throughout the entire colon, including the ascending (black arrowheads),
transverse (white arrowheads), and descending colon (gray arrowheads).
Inflammatory bowel disorder was suspected, and intestinal biopsy
established the final diagnosis of Crohn’s disease.
Eur J Nucl Med Mol Imaging
Definitive causes of fever
In 68 out of all 110 patients, a definite cause of fever was found
(62%). These included endocarditis in 12 patients, systemic ju-
venile idiopathic arthritis in 5 patients, inflammatory bowel dis-
order in 5 patients, and cholangitis in 4 patients (Table 3). In 42
patients (38%), no cause of fever was found on FDG-PET/CTor
any other diagnostic test; their diagnoses remained FUO
(Table 3).
In 53 out of the 68 patients with a confirmed cause of fever,
the cause of fever was established based on FDG-PET/CT
(Table 3).
In 15 patients, a cause of fever was found that was not
diagnosed by FDG-PET/CT. These included 5 cases of endo-
carditis (of whom 4 patients had an artificial valve), 2 cases of
systemic juvenile idiopathic arthritis, 1 single joint arthritis, 2
cases of drug-induced fever, 2 cases of Kawasaki arteritis, 1
case of systemic lupus erythematosus, 1 urinary tract infec-
tion, and 1 case of familial Mediterranean fever.
Because drug-induced fever, Kawasaki arteritis, familial
Mediterranean fever, and urinary tract infection are not to be
diagnosed with FDG-PET/CT, these six cases were not con-
sidered “false negative,” but in the absence of other signs of
inflammation, malignancy, or infection, as “true negative.”
Diagnostic performance of FDG-PET/CT
According to the reference standard, 53 FDG-PET/CT results
were true positive, 10 were false positive, 38 were true nega-
tive, and 9 were false negative. This resulted in a sensitivity of
85.5%, specificity of 79.2%, PPV of 84.1%, and NPV of
80.9% (Table 4). Among the 10 false positive results, 3
FDG-PET/CT scans were suggestive of lymphoma, 3 scans
suggestive of pulmonary infection, 2 scans suggestive of in-
flammatory bowel disorder, 1 scan indicated a soft tissue in-
fection of the leg, and 1 scan was suggestive of vasculitis. The
Table 1 Clinical characteristics of included patients (n = 110)
Characteristic Value




Number of boys:girls 54:56
Previous medical history
No medical history 26
Previous episode of unexplained fever 6
Hepatobiliary disease 22










Duration of febrile illness before FDG-PET/CT (days) 25 (31)a
Mortality within 3 months after FDG-PET/CT 8b





Low-dose unenhanced CT 110
Full-dose contrast-enhanced CT 13
Blood glucose level before scan (mmol/L) 4.9 (1.0)a
Radioactive dose used (MBq) 86 (101)a
aMedian (interquartile range)
b Causes of death: (1) liver and kidney failure, (2) thrombotic liver dis-
ease, (3) hepatic encephalopathy, (4) bone marrow failure due to mito-
chondrial myopathy and sideroblastic anemia, (5) cardiac shunt thrombo-
sis, (6) massive pulmonary bleeding, (7) hemophagocytic
lymphohistiocytosis, (8) hepatopulmonary syndrome
Table 2 Imaging and laboratory tests before FDG-PET/CT
Test Value


















White blood cell count (× 109/L) 9.8 (8.5)a
Neutrophilic granulocytes (× 109/L) 5.6 (7.0)a
Lymphocytes (× 109/L) 1.9 (1.4)a
Eosinophils (× 109/L) 0.15 (0.27)a
C-reactive protein (mg/L) 49 (75)a
Hemoglobin (mmol/L) 6.2 ± 1.1b
Hematocrit (L/L) 0.30 ± 0.055b
Mean corpuscular volume (fL) 81.7 ± 6.3b
Erythrocyte sedimentation rate (mm/h) 61 ± 39b
Thrombocytes (10^9/L) 309 (254)a
aMedian (interquartile range)
bMean (standard deviation)
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9 false negative results included five cases of endocarditis,
two cases of systemic juvenile idiopathic arthritis, one case
of systemic lupus erythematosus, and one single joint arthritis.
Treatment modifications
In 58 out of 110 patients (53%), treatment modifications were
made after FDG-PET/CT. The most common changes includ-
ed a switch in antibiotics (21 patients), starting immunosup-
pressive therapy (10 patients), and starting treatment with a
non-steroidal anti-inflammatory drug (5 patients). The same
treatment as before FDG-PET/CTwas continued in 49 out of
110 patients (45%). In 3 patients, it was not documented what
treatment was given after FDG-PET/CT (Table 5).
Factors associated with FDG-PET/CT outcome
On univariate logistic regression, leukocyte count was nega-
tively associated with finding a true positive focus of fever on
FDG-PET/CT (OR = 0.93 (95% CI 0.88–0.99) per 109
leukocytes/L increase), and CRP was positively associated
with finding a true positive focus (OR = 1.01 (95% CI 1.00–
1.01) per mg/L increase in CRP). On multivariate logistic
regression, CRP was positively associated with finding a true
positive focus of fever on FDG-PET/CT (OR = 1.01 (95% CI
1.00–1.02) per mg/L increase in CRP), while leukocyte count
was negatively associated with finding a true positive focus of
fever (OR = 0.91 (95% CI 0.85–0.97) per 109 leucocytes/L
increase). No other clinical or laboratory factors were signifi-
cantly associated with FDG-PET/CT outcome (Table 6).
Table 3 Discharge diagnosis after FDG-PET/CT








Fever of unknown origin 42 n/a Acute lymphoblastic leukemia 1 1 (100%)
Endocarditis 12 7 (58%) Hepatic aspergillus infection 1 1 (100%)
Systemic juvenile idiopathic arthritis 5 3 (60%) Castleman disease 1 1 (100%)
Inflammatory bowel disorder 5 5 (100%) Ewing sarcoma 1 1 (100%)
Cholangitis 4 4 (100%) Familial Mediterranean fever 1 n/a
Post-transplant lymphoproliferative disease 3 3 (100%) Intravenous catheter infection 1 1 (100%)
Pulmonary infection 3 3 (100%) Mixed connective tissue disorder 1 1 (100%)
Abdominal abscess 2 2 (100%) Parapharyngeal abscess 1 1 (100%)
Single joint arthritis 2 1 (50%) Polyarteritis nodosa 1 1 (100%)
Drug-induced fever 2 n/a Sacroiliitis 1 1 (100%)
Extrapulmonary tuberculosis 2 2 (100%) Sickle cell crisis 1 1 (100%)
Juvenile idiopathic arthritis 2 2 (100%) Systemic lupus erythematosus 1 0 (0%)
Kawasaki arteritis 2 n/a Soft tissue infection leg 1 1 (100%)
Mediastinitis 2 2 (100%) Tonsillitis 1 1 (100%)
Osteomyelitis 2 2 (100%) Urinary tract infection 1 n/a
Spondylodiscitis 2 2 (100%) Visceral leishmaniasis 1 1 (100%)
Takayasu arteritis 2 2 (100%)
Table 4 Sensitivity and specificity of FDG-PET/CT
Statistic Value 95% CI
Sensitivity 85.5% (53/62) 74.2–93.1%
Specificity 79.2% (38/48) 65.0–89.5%
Positive predictive value 84.1% 75.2–90.3%
Negative predictive value 80.9% 69.4–88.7%
Table 5 Changes in treatment after FDG-PET/CT
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Discussion
This study shows that FDG-PET/CT can play a valuable role in
identifying a cause of fever in children with FUO.
In 68 of all 110 patients with fever (62%), a definite cause
of fever was identified. This cause was identified on FDG-
PET/CT in 53 of all 110 patients (48%).
Previous research on the value of FDG-PET/CT in children
with FUO is limited. In a study by Jasper et al., FDG-PET/CT
was performed in 17 children with FUO. They reported a
sensitivity of FDG-PET/CT of 100% for finding a focus of
fever, but a specificity was not reported (22). It was not spec-
ified which patients were included in the sensitivity and spec-
ificity analyses, although 43% of included FDG-PET/CT
scans were performed for finding an inflammatory focus in
patients without FUO. Eighteen percent of FDG-PET/CT re-
sults were considered helpful because they excluded differen-
tial diagnoses, 24% were considered helpful because they
allowed targeted evaluation, and 59% were considered not
helpful.
In a study by Blokhuis et al., FDG-PET/CTwas performed
in 28 children. An infection was found in 7% of patients,
malignant disease in 7% of patients, non-infectious inflamma-
tory disease in 32% of patients, and in 54% of patients, no
cause of fever was found. Blokhuis et al. reported a sensitivity
of 80% and specificity of 78% for finding a cause of fever on
FDG-PET/CT (23). A definitive cause of FUO was
established in 16 patients, but this cause was found on only
8 FDG-PET/CT scans and 2 FDG-PET scans.
In our patient population, FDG-PET/CT achieved a sensi-
tivity of 85.5% and specificity of 79.2% for identifying a
cause of fever. Three out of 10 false positive FDG-PET/CT
results were suggestive of lymphoma. FDG-PET/CT has a
high sensitivity for diagnosing lymphoproliferative diseases
such as lymphoma, but low specificity. As lymphadenopathy
is a relatively common finding in patients with FUO, the use
of FDG-PET/CT to distinguish benign or reactive from
malignant lymphadenopathy is challenging (25, 26).
However, FDG-PET/CT is an excellent tool to identify an
easily accessible FDG avid lymphoid lesion for diagnostic
biopsy.
In 5 out of 9 false negative results, the diagnosis at hospital
discharge was endocarditis that was not identified on FDG-
PET/CT. Four patients had artificial valve endocarditis, and 1
patient had native valve endocarditis. FDG-PET/CT is known
to have a low sensitivity for native valve endocarditis, but a
very high sensitivity for artificial valve endocarditis (27). In 2
out of 4 cases of artificial valve endocarditis, the diagnosis
was based on clinical signs and positive blood cultures.
However, these two patients had not followed a diet low in
carbohydrates to suppress physiologic FDG uptake of the
myocardium, which may have masked pathologic FDG up-
take of the cardiac valves.
As is illustrated by these false negative results, it is impor-
tant to keep in mind that not all cases of FUO can be diag-
nosed with FDG-PET/CT. Because of various reasons, the
underlying cause of fever may not be visible on FDG-PET/
CT. Several precautions can be taken to avoid unnecessary
false negative results. Most importantly, these include adher-
ing to a diet low in carbohydrates, especially when a focus of
fever is suspected in tissues with high metabolic activity such
as the heart, and reducing dosage of corticosteroid treatment to
a minimum, especially when vasculitis is suspected. Likewise,
prolonged use of antibiotic treatment may reduce the chance
of finding a focus of infection (28). When FDG-PET/CT is
unable to detect a cause of fever, but there is still clinical
suspicion of a certain disease, additional imaging or testing
is still warranted.
In 53% of patients, treatment was modified after FDG-
PET/CT. Because of the retrospective nature of this study, it
is difficult to relate treatment modifications directly to FDG-
PET/CToutcome, especially with regard to changes within the
same class of medication (e.g., antibiotics and anti-
inflammatory agents). However, in 16 out of 53 patients with
Table 6 Factors associated with







Age 1.00 (0.94–1.06) 0.96
Gender 0.75 (0.35–1.59) 0.45
Duration of fever (before FDG-PET/CT) 1.00 (1.00–1.00) 0.50
CRP 1.01 (1.00–1.01) 0.082 1.01 (1.00–1.02) 0.013
Leukocytes 0.93 (0.88–0.99) 0.019 0.91 (0.85–0.97) 0.004
PET with full-dose contrast-enhanced CT 1.29 (0.41–4.13) 0.66
Medical history
Healthy 0.73 (0.30–1.78) 0.49
Previous episode of unexplained fever 2.25 (0.39–12.80) 0.36
Hepatobiliary disease 0.87 (0.34–2.23) 0.78
Recurrent ear/nose/throat infections 0.80 (0.17–3.73) 0.77
Cardiac abnormality 2.42 (0.77–7.62) 0.13
Chromosomal abnormality 1.08 (0.26–4.56) 0.92
Other 0.73 (0.30–1.78) 0.49
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a true positive cause of fever, a new type of treatment was
started, while this was only the case in 4 out of 38 true nega-
tive patients. Thus, a new type of treatment was three times
more likely to be started in patients with a true positive cause
of fever on FDG-PET/CT than in patients with true negative
FDG-PET/CT results.
On univariate logistic regression, only leukocyte count was
significantly associated with FDG-PET/CT outcome. On mul-
tivariate logistic regression, CRP level (positively) and leuko-
cyte count (negatively) were significantly associated with
FDG-PET/CToutcome (OR of 1.01 and 0.91 per unit increase,
respectively). Although CRP and leukocyte count are some-
times regarded as infection and inflammatory parameters that
are jointly elevated, these results illustrate that this is not always
the case. CRP levels can reach very high levels in
autoinflammatory diseases such as vasculitis and systemic ju-
venile idiopathic arthritis, while leukocyte count may be nor-
mal or only moderately elevated (29). Likewise, leukopenia
instead of leukocytosis is sometimes seen in patients with sep-
sis or systemic lupus erythematosus (30, 31). In autoimmune
disease and immunodeficiency, higher erythrocyte sedimenta-
tion rates are seen with lower levels of CRP. The different ways
in which CRP and leukocyte count are associated with disease
activity in different types of diseases likely explain the discrep-
ancy between a positive association for CRP and negative as-
sociation for leukocyte count in finding a focus of fever.
Aside from CRP level and leukocyte count, no other clin-
ical or demographic factors were significantly associated with
FDG-PET/CT outcome. Therefore, it remains challenging to
prospectively identify those patients with FUO in whom it
would be more or less likely to find a cause of fever with
FDG-PET/CT.
In the study by Jasper et al., CRP, neutrophilic
granulocytes, and thrombocytes correlated significantly with
“positive” FDG-PET or FDG-PET/CT results. However, the
definition of “positive scans” also included all scans with non-
specific FDG uptake (such as elevated FDG uptake in the
bone marrow, which is common in fever), and indeed, 49%
of all positive scans were retrospectively regarded as “not
helpful” (32). Because stand-alone FDG-PET results were al-
so included, it is also unclear which final diagnoses were
based on FDG-PET and which were based on FDG-PET/CT.
In the study by Blokhuis et al., CRP level was not associ-
ated with a true positive focus of fever on FDG-PET(/CT),
which might be due to the low number of included patients.
Also, by maintaining very strict criteria for FUO, it is ques-
tionable how well their study results can be extrapolated to the
whole population of children with FUO (33).
Our study has some limitations. First, due to its retrospective
design, there may have been selection bias. In most children
with FUO, conventional diagnostics such as radiography, ultra-
sonography, or routine blood tests were performed before
FDG-PET/CT. Only when these tests fail to identify a definite
cause of fever, children might be scheduled for FDG-PET/CT.
Therefore, the results of this study may not apply to all children
with FUO. Second, the diagnoses at hospital discharge and
results from patient follow-up were used as reference standard
for FDG-PET/CT results. Although all diagnostic test results,
clinical signs, response to treatment, and clinical follow-up
were considered in the reference diagnosis, the diagnosis at
hospital discharge was partly based on FDG-PET/CT itself
and therefore might have caused verification bias.
Conclusion
FDG-PET/CT is a valuable diagnostic tool in the evaluation of
children with FUO, since it may detect a true underlying cause
in almost half (48%) of all cases where none was found oth-
erwise. It allows full-body evaluation in patients without
disease-specific symptoms on one examination. In 58 out of
110 patients (53%), treatment modifications were made after
FDG-PET/CT, and a new type of medication (e.g., antibiotics,
immune suppression, chemotherapy) was started in 16 out of
53 children with true positive FDG-PET/CT findings. CRP
and leukocyte count were significantly associated with
FDG-PET/CT results, which may contribute to a priori assess-
ment on the outcome of FDG-PET/CT. Future research could
be aimed at evaluating more patient-specific factors to pro-
spectively estimate the added value of FDG-PET/CT in chil-
dren with FUO.
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